These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153 [TBL] [Abstract][Full Text] [Related]
9. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB; Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288 [TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003 [No Abstract] [Full Text] [Related]
13. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Hsu VM; Denton CP; Domsic RT; Furst DE; Rischmueller M; Stanislav M; Steen VD; Distler JHW; Korish S; Cooper A; Choi S; Schafer PH; Horan G; Hough DR J Rheumatol; 2018 Mar; 45(3):405-410. PubMed ID: 29093152 [TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP; Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440 [TBL] [Abstract][Full Text] [Related]
15. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623 [TBL] [Abstract][Full Text] [Related]
16. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883 [TBL] [Abstract][Full Text] [Related]
17. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399 [TBL] [Abstract][Full Text] [Related]
18. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961 [TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326 [TBL] [Abstract][Full Text] [Related]
20. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Wollin L; Trinh-Minh T; Zhang Y; Distler JHW Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]